
Opinion|Videos|August 16, 2024
Expert Perspective on the Expanding Treatment Landscape in mCRPC
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Key opinion leaders explore the expanding treament landscape for mCRPC.
Advertisement
Episodes in this series

Now Playing
- Given the evolution/expansion of the prostate cancer treatment landscape for metastatic castration-resistant prostate cancer (mCRPC), can you discuss key factors that shape your treatment approach?
- How do patient characteristics such as age, performance status, and comorbidities influence that decision?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
5 urologic oncology headlines you missed in Q2 2026
2
5 benign urology headlines you missed in Q2 2026
3
Helen L. Bernie, DO, MPH, on counseling patients through TRT and prostate cancer uncertainty
4
Advancing PROs to support survivor-centered NMIBC care
5













